Study Explores Asthma Drug’s Impact on α-Synuclein Levels

Understanding Parkinson’s Disease

Parkinson’s disease (PD) is a progressive neurological disorder characterized by symptoms such as tremors, motor difficulties, and muscle discomfort. The condition arises from the degeneration and eventual death of neurons in areas of the brain that regulate movement and muscle coordination. A key factor in this degeneration is the accumulation of misfolded α-synuclein protein within these neurons.

Targeting α-Synuclein for Treatment

Research is increasingly focusing on drugs that specifically target α-synuclein, particularly those that prevent its aggregation. Recent studies have begun to explore methods to reduce the production of α-synuclein itself.

Research Findings on Salbutamol

A recent article in the journal Science presents findings from a study that investigated the effects of various substances on the production of α-synuclein by brain cells. Researchers tested over 1,100 candidate drugs, vitamins, and supplements on cultured brain cells. Among these, salbutamol, an asthma medication, was noted for its ability to decrease the activity of the α-synuclein gene (SNCA), leading to reduced levels of the α-synuclein protein.

Salbutamol activates the β2-adrenoreceptor (β2AR), which is primarily known for its role in dilating airways. However, this activation was also found to decrease SNCA activity by enhancing histone acetylation. This process involves the addition of acetyl molecules to histone proteins, which alters their binding to DNA, thus making the gene less accessible for cellular machinery.

Impact of Salbutamol on Parkinson’s Disease Risk

To evaluate the potential impact of salbutamol on Parkinson’s disease risk, researchers reviewed the health records of over 4 million Norwegian patients over 11 years. Their findings indicated a 34% reduction in the likelihood of developing PD among individuals who had taken salbutamol at least once. Furthermore, individuals who utilized higher doses of salbutamol from 2004 to 2007 had a 50% lower risk of developing PD between 2008 and 2014 compared to those on the lowest doses. Conversely, the use of a β2AR-blocking compound was linked to an increased risk of PD.

While the overall incidence of PD in the study population was relatively low—approximately 0.1% among non-salbutamol users and less than 0.04% among users—β2AR activation demonstrated a protective effect against PD in both mice and human brain cell cultures.

Implications and Future Research Directions

These findings suggest that salbutamol may offer significant benefits for treating Parkinson’s disease, and more broadly, that β2AR activation could be a promising therapeutic approach. Given that salbutamol does not easily cross the blood-brain barrier, research into β2AR-activating compounds that can penetrate this barrier may yield beneficial results. Additionally, conducting clinical studies in more diverse populations with higher Parkinson’s disease prevalence could help clarify the role of β2AR activation in PD risk.

Clinical trials are currently in progress to further investigate these potential therapeutic strategies.

References

– http://www.sciencemag.org/news/2017/08/asthma-drug-may-thwart-parkinson-s-disease
– http://science.sciencemag.org/content/357/6354/891